Abivax is also the first company to have established “a fruitful collaboration” with the Cuban Centre for Genetic Engineering and Biotechnology (CGIB) in Havana, and the Finlay Institute (a vaccine specialist there). This is to also investigate the treatment of Hepatitis B, another major health problem in Cuba (and worldwide).
The Phase IIa trial’s observed adverse events (mainly headache, nausea and vomiting) were predominantly mild in nature. Jacques Reynes, Head of the Infectious Diseases Department at Montpellier University Hospital (France) and principal investigator of the next study with ABX464 commented:
The results of this first study in HIV-infected patients encourage us to start the next Phase IIa study in which different doses and combination with other HIV therapies will be explored.”
Research on biomarkers predicting ABX464 efficacy will also be part of the future clinical program, but the primary goal of the ABX464 clinical trials is to optimise the medicine’s effect, and eventually result in a long-lasting functional cure.
This is great news for Abivax, who have a strong commanding board to include French Biotech stars such as Domonique Constatini and Philippe Pouletty overseeing its antiviral program development.